🇺🇸 FDA

Company profile · Sponsor

Orchard

Orchard Therapeutics (Netherlands) B.V.

E60F99D · EMA pharma EU
Pipeline
5
Drugs
0
Patents
0

Quick answer

Orchard (E60F99D) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 5 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E60F99D
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (5)

Search pipeline →

  1. LARONIDASE, OTL-203, -, RITUXIMAB, FLUDARABINE, BUSULFAN, PLERIXAFOR

    Orchard

    Mucopolysaccharidosis type I, Hurler Syndrome

    phase 3 small molecule active

    1 trial

  2. Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion

    Orchard

    Metachromatic Leukodystrophy (MLD)

    phase 3 small molecule active

    1 trial

  3. Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion

    Orchard

    Metachromatic Leukodystrophy (MLD) is an autosomal recessive disorder caused by mutations

    phase 3 small molecule active

    1 trial

  4. LENOGRASTIM , RITUXIMAB, BUSULFAN , FLUDARABINE , PLERIXAFOR , OTL-203

    Orchard

    Mucopolysaccharidosis type I Hurler

    phase 2 small molecule active

    1 trial

  5. Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion

    Orchard

    Metachromatic Leukodystrophy (MLD)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Orchard?

Orchard (E60F99D) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 5 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Orchard sponsor?

We track 5 ClinicalTrials.gov-linked programs for Orchard, including LARONIDASE, OTL-203, -, RITUXIMAB, FLUDARABINE, BUSULFAN, PLERIXAFOR and 4 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Orchard company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.